While this may represent a well-balanced equilibrium under healthy conditions, the tumor setting leads to its disruption with upregulation of inhibitory ligands like PD-L1 on glioma cells and CD86 on GAMs, leading to the dysfunctional state seen in the glioma-residing CD8+ Trm cells. This evidence concerns the gene CD8A and central nervous system cancer.